These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 3791955)
1. Phytocompounds and their molecular targets in immunomodulation: a review. Cherian A; Vadivel V; Thiruganasambandham S; Madhavankutty S J Basic Clin Physiol Pharmacol; 2023 Sep; 34(5):577-590. PubMed ID: 34786892 [TBL] [Abstract][Full Text] [Related]
2. Screening for chemoimmunotherapeutics, success rate and predictivity of models: a five years experience. Sedlacek HH; Dickneite G; Schorlemmer HU Behring Inst Mitt; 1986 Jun; (80):74-92. PubMed ID: 3530237 [TBL] [Abstract][Full Text] [Related]
3. Three new agents for immunotherapy trials: azimexon, bestatin, and tuftsin. Mathé G; Florentin I; Bruley-Rosset M; Goutner A; Serrou B Recent Results Cancer Res; 1982; 80():331-3. PubMed ID: 6977171 [No Abstract] [Full Text] [Related]
4. Ex vivo and in vivo characterization of biological response modifiers (BRMs). Masihi KN; Talmadge JE Dev Biol Stand; 1992; 77():143-5. PubMed ID: 1426655 [No Abstract] [Full Text] [Related]
6. Chemotherapeutics: a questionable or a promising project. Sedlacek HH; Dickneite G; Schorlemmer HU Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):99-119. PubMed ID: 3791955 [TBL] [Abstract][Full Text] [Related]
7. How to find immunomodulators--a look backward and forward. Sedlacek HH Behring Inst Mitt; 1984 May; (74):122-31. PubMed ID: 6383321 [TBL] [Abstract][Full Text] [Related]
8. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems. Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322 [TBL] [Abstract][Full Text] [Related]
9. Current status and perspectives of immunomodulators of microbial origin. Chihara G; Maeda YY; Hamuro J Int J Tissue React; 1982; 4(3):207-25. PubMed ID: 6815071 [TBL] [Abstract][Full Text] [Related]
10. Antigen-Specific Tolerization and Targeted Delivery as Therapeutic Strategies for Autoimmune Diseases. Shakya AK; Nandakumar KS Trends Biotechnol; 2018 Jul; 36(7):686-699. PubMed ID: 29588069 [TBL] [Abstract][Full Text] [Related]
11. Adoptive cellular therapy of malignancy. Chang AE; Geiger JD; Sondak VK; Shu S Arch Surg; 1993 Nov; 128(11):1281-90. PubMed ID: 8239992 [TBL] [Abstract][Full Text] [Related]